

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Luc Teyton	10/17/2008
RECEIVING PARTY DATA	
Name:	The Scripps Research Institute
Street Address:	10550 North Torrey Pines Road
City:	La Jolla
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12296169
CORRESPONDENCE DATA	
Fax Number:	(608)283-2275
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	608-257-3501
Email:	madipdocket@michaelbest.com
Correspondent Name:	Michael Best & Friedrich LLP
Address Line 1:	One South Pinckney Street, Suite 700
Address Line 2:	P.O. Box 1806
Address Line 4:	Madison, WISCONSIN 53701-1806
ATTORNEY DOCKET NUMBER:	017968-9011-US01 WMW
NAME OF SUBMITTER:	Wendy M. Ward
Total Attachments: 2 source=B1614456#page1.tif source=B1614456#page2.tif	

OP \$40.00 12296169

ASSIGNMENT

Pursuant to my obligation to The Scripps Research Institute (hereinafter referred to as "Assignee"), a Not-for-Profit California Corporation having its principal place of business at:

10550 North Torrey Pines Road
La Jolla, CA 92037

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, I:

Luc Teyton
14226 Pinewood Drive
Del Mar, CA 92014

confirm my obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, my entire right, title and interest

(1) in and to an invention entitled MODIFIED α -GALACTOSYL CERAMIDES FOR STAINING AND STIMULATING NATURAL KILLER T CELLS (Atty. File No. 017968-9011-US01) the specification of which was filed with my authority on April 9, 2007 as International Patent Application No. PCT/US2007/066250 (hereinafter the "PCT application") which application claims the benefit of United States Provisional Patent Application No. 60/790,096, filed April 7, 2006 (hereinafter the "U.S. provisional patent application");

(2) in and to the PCT application and the U.S. provisional patent application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue applications) based upon said invention or claiming the benefit of the PCT application, or the U.S. provisional patent application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT application and the U.S. provisional patent application.

I agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application and the U.S. provisional patent application.

I hereby agree that I will, upon demand of Assignee, its successors or assigns, and without further consideration to me, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by me.

And the Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

Date

10 17 08

Luc Teyton



Q:\CLIENT\017968\9011\B1590917.0